ProQR Therapeutics Toekomstige groei

Future criteriumcontroles 2/6

De winst van ProQR Therapeutics zal naar verwachting dalen met 11.1% per jaar, terwijl de jaarlijkse omzet naar verwachting zal groeien met 24.3% per jaar. De winst per aandeel zal naar verwachting dalen met 4.2% per jaar. Het rendement op het eigen vermogen zal over 3 jaar naar verwachting -115.2% zijn.

Belangrijke informatie

-11.1%

Groei van de winst

-4.2%

Groei van de winst per aandeel

Biotechs winstgroei	27.3%
Inkomstengroei	24.3%
Toekomstig rendement op eigen vermogen	-115.2%
Dekking van analisten	Low
Laatst bijgewerkt	29 Oct 2024

Recente toekomstige groei-updates

Recent updates

There's Reason For Concern Over ProQR Therapeutics N.V.'s (NASDAQ:PRQR) Massive 118% Price Jump

Oct 23

ProQR Therapeutics N.V. (NASDAQ:PRQR) Investors Are Less Pessimistic Than Expected

Jul 15

Broker Revenue Forecasts For ProQR Therapeutics N.V. (NASDAQ:PRQR) Are Surging Higher

May 29

Despite Lacking Profits ProQR Therapeutics (NASDAQ:PRQR) Seems To Be On Top Of Its Debt

Mar 17

ProQR says EU regulator seeks additional trial for lead candidate

Aug 11

Here's Why ProQR Therapeutics (NASDAQ:PRQR) Can Manage Its Debt Despite Losing Money

Nov 10

Investment Case On ProQR Therapeutics Gets More Enticing

Oct 01

ProQR Therapeutics (NASDAQ:PRQR) Has Debt But No Earnings; Should You Worry?

Aug 04

ProQR Therapeutics: Looks Interesting Ahead Of Next Year's Pivotal Data

Jun 20

It's Unlikely That ProQR Therapeutics N.V.'s (NASDAQ:PRQR) CEO Will See A Huge Pay Rise This Year

May 13

ProQR Therapeutics offers a de-risked opportunity: Stifel

May 03

If You Had Bought ProQR Therapeutics' (NASDAQ:PRQR) Shares A Year Ago You Would Be Down 42%

Mar 08

Could The ProQR Therapeutics N.V. (NASDAQ:PRQR) Ownership Structure Tell Us Something Useful?

Feb 01

ProQR concludes enrollment in mid-stage cell therapy trial in a rare eye disorder

Jan 07

ProQR Therapeutics (NASDAQ:PRQR) Has Debt But No Earnings; Should You Worry?

Dec 28

A Look At ProQR Therapeutics' (NASDAQ:PRQR) Share Price Returns

Dec 01

Winst- en omzetgroeiprognoses

NasdaqCM:PRQR - Toekomstschattingen van analisten en financiële gegevens uit het verleden (EUR Millions )
Datum	Inkomsten	Inkomsten	Vrije kasstroom	Geldmiddelen uit operationele activiteiten	Gem. Aantal analisten
12/31/2026	10	-49	-54	-69	3
12/31/2025	14	-29	-18	-32	5
12/31/2024	27	-26	N/A	-29	5
6/30/2024	16	-22	-28	-34	N/A
3/31/2024	11	-27	-32	-38	N/A
12/31/2023	7	-28	28	22	N/A
9/30/2023	5	-37	8	9	N/A
6/30/2023	4	-54	1	1	N/A
3/31/2023	4	-59	-4	-3	N/A
12/31/2022	4	-64	-69	-69	N/A
9/30/2022	4	-69	-48	-47	N/A
6/30/2022	4	-61	-40	-40	N/A
3/31/2022	3	-63	-35	-35	N/A
12/31/2021	2	-61	-26	-26	N/A
9/30/2021	2	-57	-42	-42	N/A
6/30/2021	2	-55	-44	-43	N/A
3/31/2021	1	-43	-45	-44	N/A
12/31/2020	1	-47	-48	-47	N/A
9/30/2020	1	-52	-48	-47	N/A
6/30/2020	1	-51	-47	-46	N/A
3/31/2020	2	-58	-47	-47	N/A
12/31/2019	2	-56	-45	-44	N/A
9/30/2019	3	-51	-41	-41	N/A
6/30/2019	5	-45	-37	-37	N/A
3/31/2019	6	-40	-32	-31	N/A
12/31/2018	6	-37	-29	-28	N/A
9/30/2018	4	-35	-28	-28	N/A
6/30/2018	2	-40	-32	-31	N/A
3/31/2018	1	-44	N/A	-36	N/A
12/31/2017	1	-44	N/A	-35	N/A
9/30/2017	1	-41	N/A	-34	N/A
6/30/2017	1	-41	N/A	-37	N/A
3/31/2017	1	-39	N/A	-35	N/A
12/31/2016	2	-39	N/A	-34	N/A
9/30/2016	3	-36	N/A	-34	N/A
6/30/2016	3	-33	N/A	-29	N/A
3/31/2016	3	-31	N/A	-27	N/A
12/31/2015	3	-21	N/A	-24	N/A
9/30/2015	3	-17	N/A	-22	N/A
6/30/2015	1	-14	N/A	-20	N/A
3/31/2015	1	-10	N/A	-18	N/A
12/31/2014	0	-12	N/A	-14	N/A
9/30/2014	0	-12	N/A	-10	N/A
6/30/2014	0	-9	N/A	-7	N/A
3/31/2014	0	-5	N/A	-4	N/A
12/31/2013	0	-3	N/A	-2	N/A

Toekomstige groeivoorspellingen analisten

Verdiensten versus spaarpercentage: De verwachting is dat PRQR de komende 3 jaar verliesgevend zal blijven.

Winst versus markt: De verwachting is dat PRQR de komende 3 jaar verliesgevend zal blijven.

Hoge groeiwinsten: De verwachting is dat PRQR de komende 3 jaar verliesgevend zal blijven.

Omzet versus markt: De omzet van PRQR ( 24.3% per jaar) zal naar verwachting sneller groeien dan de markt US ( 8.8% per jaar).

Hoge groei-inkomsten: De omzet van PRQR ( 24.3% per jaar) zal naar verwachting sneller groeien dan 20% per jaar.

Groeiprognoses winst per aandeel

Toekomstig rendement op eigen vermogen

Toekomstige ROE: Er wordt voorspeld dat PRQR binnen 3 jaar verliesgevend zal zijn.

ProQR Therapeutics Toekomstige groei

Future criteriumcontroles 2/6

Belangrijke informatie

Recente toekomstige groei-updates

Price target increased by 40% to US$5.73

Consensus revenue estimates increase by 35%

Consensus revenue estimates increase by 28%

Consensus revenue estimates increase by 64%, EPS downgraded

Consensus revenue estimates increase by 11%

Consensus revenue estimates increase by 15%

Recent updates

Price target increased by 40% to US$5.73

ProQR Therapeutics N.V. has completed a Follow-on Equity Offering in the amount of $63 million.

There's Reason For Concern Over ProQR Therapeutics N.V.'s (NASDAQ:PRQR) Massive 118% Price Jump

ProQR Therapeutics N.V. has filed a Follow-on Equity Offering.

ProQR Therapeutics N.V. has filed a Follow-on Equity Offering in the amount of $75 million.

Consensus revenue estimates increase by 35%

Second quarter 2024 earnings: EPS exceeds analyst expectations while revenues lag behind

ProQR Therapeutics N.V. (NASDAQ:PRQR) Investors Are Less Pessimistic Than Expected

Broker Revenue Forecasts For ProQR Therapeutics N.V. (NASDAQ:PRQR) Are Surging Higher

Consensus revenue estimates increase by 28%

ProQR Announces Preclinical Proof of Concept Data for AX-0810 Axiomer™ RNA Editing Program Targeting NTCP for Cholestatic Diseases

ProQR Therapeutics N.V., Annual General Meeting, May 22, 2024

ProQR Therapeutics N.V., Annual General Meeting, May 22, 2024

ProQR Therapeutics N.V. Achieves Successful Defense of New Challenge to its Axiomer™ IP Portfolio

Is ProQR Therapeutics (NASDAQ:PRQR) Using Too Much Debt?

Consensus revenue estimates increase by 64%, EPS downgraded

Third quarter 2023 earnings released: €0.07 loss per share (vs €0.33 loss in 3Q 2022)

New major risk - Revenue and earnings growth

Consensus revenue estimates increase by 11%

Laboratoires Théa S.A.S. acquired Sepofarsen and Ultevursen Ophthalmic Assets from ProQR Therapeutics N.V. (NasdaqCM:PRQR) for approximately €170 million.

New minor risk - Share price stability

Health Check: How Prudently Does ProQR Therapeutics (NASDAQ:PRQR) Use Debt?

Third quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

New major risk - Revenue and earnings growth

New minor risk - Share price stability

Consensus revenue estimates increase by 15%

Consensus revenue estimates fall by 16%

New major risk - Revenue and earnings growth

Second quarter 2023 earnings: EPS and revenues exceed analyst expectations

Laboratoires Théa S.A.S. agreed to acquire Sepofarsen and Ultevursen Ophthalmic Assets from ProQR Therapeutics N.V. (NasdaqCM:PRQR) for approximately €135 million.

Is ProQR Therapeutics (NASDAQ:PRQR) Using Too Much Debt?

Consensus revenue estimates decrease by 25%

Consensus EPS estimates upgraded to €0.24 loss, revenue downgraded

Price target decreased by 9.2% to US$3.82

ProQR Therapeutics N.V. Approves the Appointment of Theresa Heggie and Begoña Carreño as Supervisory Board Member

First quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Forecast to breakeven in 2023

Full year 2022 earnings: EPS in line with expectations, revenues disappoint

Despite Lacking Profits ProQR Therapeutics (NASDAQ:PRQR) Seems To Be On Top Of Its Debt

Price target increased to US$3.25

Consensus forecasts updated

Third quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

ProQR Therapeutics N.V. Appoints Jurriaan Dekkers as Chief Financial Officer

Consensus forecasts updated

ProQR Therapeutics N.V. to Focus Exclusively on Axiomer RNA-editing Technology and Partner Ophthalmology Programs

Consensus revenue estimates increase by 25%

ProQR says EU regulator seeks additional trial for lead candidate

Second quarter 2022 earnings: EPS and revenues exceed analyst expectations

ProQR Therapeutics N.V. Appoints Rene Beukema as Member of Management Board

ProQR Therapeutics N.V., Annual General Meeting, Jun 30, 2022

Consensus estimates of losses per share improve by 11%

First quarter 2022 earnings: EPS and revenues exceed analyst expectations

Price target decreased to US$3.29

Price target decreased to US$3.64

ProQR Therapeutics N.V. Announces Additional Sepofarsen Illuminate Trial Analyses and Provides Update on Company Strategy

Foundation Fighting Blindness and InformedDNA Partner to Engage and Screen Patients for Proqr's Pivotal Usher Syndrome and Retinitis Pigmentosa Clinical Trials

Full year 2021 earnings: EPS exceeds analyst expectations while revenues lag behind

Price target decreased to US$13.50

ProQR Announces Top-Line Results from Phase 2/3 Illuminate Trial of Sepofarsen in CEP290-mediated LCA10

ProQR Therapeutics N.V. Announces Last Patient Has Completed 12 Month Visit in Phase 2/3 Illuminate Trial of Sepofarsen

ProQR Therapeutics N.V. Announces First Patients Dosed in Phase 2/3 Pivotal Trials of QR-421A for USH2A Mediated Retinitis Pigmentosa

Here's Why ProQR Therapeutics (NASDAQ:PRQR) Can Manage Its Debt Despite Losing Money

Investment Case On ProQR Therapeutics Gets More Enticing

Consensus forecasts updated

Phoenicis Therapeutics Inc. acquired Wings Therapeutics, Inc from ProQR Therapeutics N.V. (NasdaqGM:PRQR) and others.

ProQR Therapeutics (NASDAQ:PRQR) Has Debt But No Earnings; Should You Worry?

ProQR Therapeutics: Looks Interesting Ahead Of Next Year's Pivotal Data

It's Unlikely That ProQR Therapeutics N.V.'s (NASDAQ:PRQR) CEO Will See A Huge Pay Rise This Year

Consensus forecasts updated